Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1157/13108809 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploiting Cancer Dormancy Signaling Mechanisms in Epithelial Ovarian Cancer Through Spheroid and Organoid Analysis.
Cells
January 2025
The Mary and John Knight Translational Ovarian Cancer Research Unit, Verspeeten Family Cancer Centre, London, ON N6A 5W9, Canada.
Epithelial ovarian cancer (EOC) exhibits a unique mode of metastasis, involving spheroid formation in the peritoneum. Our research on EOC spheroid cell biology has provided valuable insights into the signaling plasticity associated with metastasis. We speculate that EOC cells modify their biology between tumour and spheroid states during cancer dormancy, although the specific mechanisms underlying this transition remain unknown.
View Article and Find Full Text PDFHigh-Grade Serous Ovarian Carcinoma Presenting With Massive Pleural Effusion in the Absence of Ascites: A Case Report and Review of the Literature.
Cureus
December 2024
Pulmonary and Critical Care Medicine, Community Health Network, Indianapolis, USA.
Pleural effusion as an initial presentation of malignancy poses significant diagnostic challenges, particularly when linked to gynecologic cancers. We discuss the case of a 53-year-old female who presented with progressive dyspnea and a massive right-sided pleural effusion. Cytological analysis of the pleural fluid revealed malignant cells and immunohistochemical staining confirmed high-grade serous carcinoma (HGSC) of ovarian origin.
View Article and Find Full Text PDFStudy protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancer.
BMJ Open
December 2024
University College London Hospitals NHS Foundation Trust, London, UK
Introduction: Adaptive ChemoTherapy for Ovarian cancer (ACTOv) is a phase II, multicentre, randomised controlled trial, evaluating an adaptive therapy (AT) regimen with carboplatin in women with relapsed, platinum-sensitive high-grade serous or high-grade endometrioid cancer of the ovary, fallopian tube and peritoneum whose disease has progressed at least 6 months after day 1 of the last cycle of platinum-based chemotherapy. AT is a novel, evolutionarily informed approach to cancer treatment, which aims to exploit intratumoral competition between drug-sensitive and drug-resistant tumour subpopulations by modulating drug dose according to a patient's own response to the last round of treatment. ACTOv is the first clinical trial of AT in this disease setting.
View Article and Find Full Text PDFPediatric Borderline Ovarian Tumors: A Retrospective Study of 15 Cases at a Single Institution.
J Pediatr Hematol Oncol
January 2025
Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX.
Borderline ovarian tumors (BOTs) are rare in pediatric populations and typically follow an indolent clinical course with few reported recurrences. Consequently, guidelines for pediatric BOT management are minimal. We retrospectively examined the management of 15 adolescent patients who underwent BOT resection at our institution over 14 years, with a specific focus on recurrence.
View Article and Find Full Text PDFThe International System for Serous Fluid Cytopathology (TIS) survey in preparation for TIS 2.0.
J Am Soc Cytopathol
December 2024
Department of Cellular Pathology, Guy's & St. Thomas' NHS Foundation Trust, London, UK.
Introduction: The International System for Serous Fluid Cytopathology (TIS) has gained acceptance and has led to literature validating original concepts and suggesting refinements. In preparation for the second edition of TIS, editors generated a survey to solicit experience with and opinions about TIS.
Materials And Methods: An online survey available from March 8 to June 15, 2024, included 56 questions, offered in 7 languages, related to the practice of serous fluid cytopathology.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!